A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT, BOTH COMBINED WITH A CDK4/6 INHIBITOR, IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY

881CO44657-NCT06065748Open (affiliates only)A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT, BOTH COMBINED WITH A CDK4/6 INHIBITOR, IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPYCO44657NCT06065748IndustrialAdultTreatmentIIIIll-Defined Sites - inactiveWalsh, ElaineMedstar Washington Hospital CenterBreastOncology GroupLombardi Comprehensive Cancer Center (LCCC); Oncology PFS7263Julie CastleJulie Castle+1 202-687-2209bickmorj@georgetown.eduClinical Research Nurse 7311Antonella NovielliAntonella Novielli+1 202-784-3923+1 202-687-3372noviella@georgetown.eduClinical Research Nurse 2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>